Cite
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
MLA
Sonneveld, P., et al. “Carfilzomib, Pomalidomide, and Dexamethasone As Second-Line Therapy for Lenalidomide-Refractory Multiple Myeloma.” Sonneveld , P , Zweegman , S , Cavo , M , Nasserinejad , K , Broijl , A , Troia , R , Pour , L , Croockewit , S , Corradini , P , Patriarca , F , Wu , KL , Droogendijk , J , Bos , G , Hajek , R , Petrucci , MT , Ypma , P , Zojer , N , Minnema , MC & Boccadoro , M 2022 , ’ Carfilzomib, Pomalidomide, and Dexamethasone As Second-Line Therapy for Lenalidomide-Refractory Multiple Myeloma ’ , HemaSphere , Vol. 6 , No. 10 , Pp. E786 , 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1410089700&authtype=sso&custid=ns315887.
APA
Sonneveld, P., Zweegman, S., Cavo, M., Nasserinejad, K., Broijl, A., Troia, R., Pour, L., Croockewit, S., Corradini, P., Patriarca, F., Wu, K., Droogendijk, J., Bos, G., Hajek, R., Petrucci, M., Ypma, P., Zojer, N., Minnema, M., & Boccadoro, M. (2022). Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma. Sonneveld , P , Zweegman , S , Cavo , M , Nasserinejad , K , Broijl , A , Troia , R , Pour , L , Croockewit , S , Corradini , P , Patriarca , F , Wu , KL , Droogendijk , J , Bos , G , Hajek , R , Petrucci , MT , Ypma , P , Zojer , N , Minnema , MC & Boccadoro , M 2022 , ’ Carfilzomib, Pomalidomide, and Dexamethasone As Second-Line Therapy for Lenalidomide-Refractory Multiple Myeloma ’ , HemaSphere , Vol. 6 , No. 10 , Pp. E786 .
Chicago
Sonneveld, P, S Zweegman, M Cavo, K Nasserinejad, A Broijl, R Troia, L Pour, et al. 2022. “Carfilzomib, Pomalidomide, and Dexamethasone As Second-Line Therapy for Lenalidomide-Refractory Multiple Myeloma.” Sonneveld , P , Zweegman , S , Cavo , M , Nasserinejad , K , Broijl , A , Troia , R , Pour , L , Croockewit , S , Corradini , P , Patriarca , F , Wu , KL , Droogendijk , J , Bos , G , Hajek , R , Petrucci , MT , Ypma , P , Zojer , N , Minnema , MC & Boccadoro , M 2022 , ’ Carfilzomib, Pomalidomide, and Dexamethasone As Second-Line Therapy for Lenalidomide-Refractory Multiple Myeloma ’ , HemaSphere , Vol. 6 , No. 10 , Pp. E786 . http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1410089700&authtype=sso&custid=ns315887.